DelveInsight’s “Chlamydia Infections Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chlamydia Infections pipeline landscapes. It comprises Chlamydia Infections pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chlamydia Infections therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chlamydia Infections pipeline products.
Some of the key takeaways from the Chlamydia Infections Pipeline Report
Get an overview of pipeline landscape @ Chlamydia Infections Clinical Trials Analysis
Chlamydia can infect both men and women. Chlamydial Infections are treated primarily by administering antibiotics such as Azithromycin, Doxycycline, Ofloxacin.
Chlamydia Infections Emerging Drugs
Eurocine Vaccines AB is developing a Chlamydia Vaccine Candidate. They have successfully identified sections of the MOMP (Major Outer Membrane Protein) in the bacterium Chlamydia trachomatis – sequences that can be used to stimulate an immune response. The specially designed protein chains are essential for the creation of the vaccine and are patent protected.
Research and DevelopmentInitial studies have proven the active protein to be very immunogenic and well-tolerated even without an adjuvant.Three major pre-clinical studies have been performed in mice, resulting in positive antibody and T-cell responses. The current development involves; 1) setting up an industrially scalable manufacturing process to ensure high-quality supply to future studies – 1st – 4th quarter 2021; 2) to manufacture study products for the planned clinical study according to GMP – 2nd quarter 2022; and 3) to design a Phase I clinical trial to be started in the fall of 2022.
For further information, refer to the detailed report @ Chlamydia Infections Pipeline Therapeutics
Scope of Chlamydia Infections Pipeline Drug Insight
Key Questions regarding Current Chlamydia Infections Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
1
Chlamydia Infections Report Introduction
2
Chlamydia Infections Executive Summary
3
Chlamydia Infections Overview
4
Chlamydia Infections – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
5
Chlamydia Infections Pipeline Therapeutics
6
Chlamydia Infections Late Stage Products (Registered)
7
Chlamydia Infections Late Stage Products (Phase III)
7.1
EVO100: Evofem Biosciences
8
Chlamydia Infections Mid Stage Products (Phase II)
9
Chlamydia Infections Early Stage Products (Phase I)
10
Chlamydia Infections Pre-clinical and Discovery Stage Products
10.1
VPI-201: Vault Pharma
11
Chlamydia Infections Therapeutic Assessment
12
Chlamydia Infections Inactive Products
13
Company-University Collaborations (Licensing/Partnering) Analysis
14
Chlamydia Infections Key Companies
15
Chlamydia Infections Key Products
16
Chlamydia Infections Unmet Needs
17
Chlamydia Infections Market Drivers and Barriers
18
Chlamydia Infections Future Perspectives and Conclusion
19
Chlamydia Infections Analyst Views
20
Appendix
21
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chlamydia-infections-pipeline-insight